Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

Opinion|Videos|February 11, 2025

Reducing Recurrence in NMIBC and Novel Treatment Approaches on the Horizon

Experts consider other pipeline treatments for non-muscle invasive bladder cancer (NMIBC), including new injectable options being explored.

Episodes in this series

EP. 1 A Comprehensive Overview of NMIBC

EP. 1 A Comprehensive Overview of NMIBC

EP. 2 Standard of Care: Staging Considerations and Establishing Patient-Provider Relationships

EP. 2 Standard of Care: Staging Considerations and Establishing Patient-Provider Relationships

EP. 3 Navigating Therapies for BCG-Unresponsive NMIBC: Immunotherapies and Chemotherapies

EP. 3 Navigating Therapies for BCG-Unresponsive NMIBC: Immunotherapies and Chemotherapies

EP. 4 New Horizons in NMIBC: Pipeline Innovations and Clinical Perspectives

EP. 4 New Horizons in NMIBC: Pipeline Innovations and Clinical Perspectives

EP. 5 Reducing Recurrence in NMIBC and Novel Treatment Approaches on the Horizon

EP. 5 Reducing Recurrence in NMIBC and Novel Treatment Approaches on the Horizon

EP. 6 Practical Patient-Centered Logistics: Providing Care to Patients With NMIBC

EP. 6 Practical Patient-Centered Logistics: Providing Care to Patients With NMIBC

EP. 7 The Mental Health Impact of NMIBC Treatment: Management With Your Patient

EP. 7 The Mental Health Impact of NMIBC Treatment: Management With Your Patient

EP. 8 Navigating The Future of NMIBC Trails: Key Insights and Takeaways

EP. 8 Navigating The Future of NMIBC Trails: Key Insights and Takeaways

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Latest CME

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Arizona

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Arizona

Surabhi Amar, MD, MHA, MBBS; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Wisconsin

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Wisconsin

Scott T. Tagawa, MD, MS, FACP, FASCO; Kate Baxstrom, MD

DSUI Urology on the Beach

In-Person Event

DSUI Urology on the Beach

January 16-18, 2026

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Aaron D. Berger, MD

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Jason M. Hafron, MD

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Stacy Loeb, MD, MSc, PhD (Hon)

Trending on Urology Times

FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures

Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC

Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study

BOND-003: Cretostimogene yields durable 24-month responses in high-grade NMIBC

Michael Cookson, MD, discusses new strategies for treatment intensification in prostate cancer

© 2025 MJH Life Sciences^®

All rights reserved.